YS Biopharma Co., Ltd. (NASDAQ:YS) Sees Large Growth in Short Interest

YS Biopharma Co., Ltd. (NASDAQ:YS) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 706,300 shares, a growth of 198.5% from the August 15th total of 236,600 shares. Currently, 3.5% of the company’s stock are short sold. Based on an average daily volume of 1,330,000 shares, the days-to-cover ratio is currently 0.5 days.

YS Biopharma Stock Down 2.0 %

YS opened at $0.99 on Thursday. YS Biopharma has a 12-month low of $0.75 and a 12-month high of $12.93. The firm has a market capitalization of $25.49 million, a PE ratio of 1.40 and a beta of -0.38. The company has a 50 day simple moving average of $1.22. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.26 and a current ratio of 1.54.

YS Biopharma (NASDAQ:YS) last issued its quarterly earnings data on Tuesday, August 15th. The company reported ($0.10) earnings per share for the quarter. The firm had revenue of $24.40 million for the quarter.

Institutional Trading of YS Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of YS Biopharma during the second quarter worth approximately $31,000. Prelude Capital Management LLC acquired a new stake in shares of YS Biopharma during the 2nd quarter worth approximately $44,000. Barclays PLC acquired a new stake in shares of YS Biopharma during the 2nd quarter worth approximately $150,000. Snow Lake Management LP acquired a new stake in shares of YS Biopharma during the 1st quarter worth approximately $2,899,000. Finally, Hhlr Advisors LTD. acquired a new stake in shares of YS Biopharma during the 1st quarter worth approximately $1,203,000. Institutional investors and hedge funds own 43.45% of the company’s stock.

About YS Biopharma

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.